靶向免疫检查点PD-1/PD-L1的肿瘤分子影像学研究进展  

Advances of molecular imaging of immune checkpoint targeting PD-1/PD-L1 in tumors

作　　者：邢岩[1] 赵晋华[1] Xing Yan;Zhao Jinhua(Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, China)

机构地区：[1]上海交通大学附属第一人民医院核医学科,200080

出　　处：《国际放射医学核医学杂志》2019年第4期356-360,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：上海申康发展中心促进市级医院临床技能与临床创新三年行动计划(16CR3052A).

摘　　要：程序化细胞死亡受体-1 (PD-1)及其配体(PD-L1)抑制剂通过阻断PD-1与PD-L1的结合使负向调控信号受阻,重新激活T淋巴细胞,增强免疫应答。临床试验结果显示PD-1/PD-L1抑制剂对多种肿瘤有明确的疗效,且疗效与肿瘤PD-1/PD-L1的表达水平相关。因此在免疫治疗之前检测患者PD-1/PD-L1的表达水平对筛选可能获益的患者、预测免疫治疗反应尤为重要。靶向PD-1/PD-L1的分子影像学方法能够在活体内无创、全面、准确地显示肿瘤PD-1及PD-L1的表达水平,成为国内外的研究热点。笔者对靶向PD-1/PD-L1肿瘤分子影像学的研究进展作一综述。Programmed cell death-1 (PD-1) and its ligand (PD-L1) inhibitors can inhibit the PD-1 and PD-L1 combination to block negative control signals. This condition leadings to the activity of T lymphocytes and the enhancement of immune responses. Clinical studies have shown that PD-1/PD-L1 inhibitors have a definite effect on a broad set of malignancies, but a substantial number of patients do not respond. Predicting the immunotherapy response by evaluating the expression of PD-1 and PD-L1 is urgently needed. Molecular imaging modalities, such as PET, SPECT, optical imaging, and MRI, can noninvasively and dynamically detect the overall expression of PD-1/PD-L1 in patients. They can help in selecting patients who are suitable for immunotherapy and monitor the tumor response. This review describes the current status and progress of molecular imaging targeting PD-1/PD-L1 in tumors.

关 键 词：肿瘤 免疫治疗 程序化细胞死亡受体-1 程序化细胞死亡配体-1 分子影像 

分 类 号：R730.4[医药卫生—肿瘤]